
Huntington's Disease Market To Evolve Rapidly Over The Next Decade By 2034, Delveinsight Observes Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage

The Key Huntington's Disease Companies in the market include - Teva Pharmaceutical, Annexon Biosciences, Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others.
DelveInsight's “Huntington's Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Huntington's Disease, historical and forecasted epidemiology as well as the Huntington's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Huntington's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Huntington's Disease Market Forecast
Some of the key facts of the Huntington's Disease Market Report:
The Huntington's Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
In September 2035, UniQure reported positive top-line results from its Phase I/II study of AMT-130, a one-time gene therapy for Huntington's disease (HD). Top-line data provides a rapid summary of key study results at a predetermined timepoint. The update indicates that AMT-130 significantly slows symptom progression and met the trial's primary endpoint, marking the first time a therapy has demonstrated the ability to alter the course of HD in a clinical setting.
In June 2025, Skyhawk Therapeutics, Inc., a clinical-stage biotech company focused on developing small molecule therapies that target RNA, has announced the dosing of the first patient in its Phase 2/3 FALCON-HD trial of SKY-0515. This investigational oral RNA splicing modulator is being evaluated for the treatment of Huntington's disease (HD). SKY-0515 is designed to lower the levels of HTT and PMS1 proteins, both of which contribute significantly to HD progression. In a Phase 1 trial involving healthy volunteers, the therapy showed a dose-dependent reduction in HTT mRNA, with an average 72% decrease at the highest dose tested, and was generally well tolerated. The Phase 1 study in HD patients, initiated in January 2025, also completed enrollment ahead of schedule in March 2025.
In December 2024, Novartis entered into an exclusive licensing agreement with PTC Therapeutics to develop and commercialize PTC518, a novel small molecule aimed at targeting the underlying cause of Huntington's disease. This collaboration represents a strategic initiative by Novartis to advance treatment options in the neurodegenerative disease space, particularly for Huntington's disease, which currently lacks approved therapies capable of stopping or reversing its progression.
In September 2024, Skyhawk Therapeutics, Inc., a clinical-stage biotech company focused on developing innovative small molecule therapies targeting RNA, announced that additional positive topline results from Parts A and B of its Phase 1 clinical trial of SKY-0515 will be presented at the European Huntington's Disease Network and Enroll-HD 2024 meeting, taking place from September 12-14, 2024, in Strasbourg, France.
In September 2024, Vico Therapeutics, a clinical-stage genetic medicines company, announced positive interim results from its ongoing Phase I/IIa trial of VO659, an investigational treatment for Huntington's disease. The findings indicate a notable reduction in mutant huntingtin protein levels in the cerebrospinal fluid of treated patients. VO659 is an allele-preferential antisense oligonucleotide (ASO) therapy designed to target the CAG repeat expansion responsible for Huntington's and other polyglutamine disorders.
In July 2024, uniQure N.V. (NASDAQ: QURE) , a prominent gene therapy company dedicated to developing breakthrough treatments for patients with serious medical conditions, released updated interim data from its ongoing Phase I/II clinical trials of AMT-130 for Huntington's disease. The data includes follow-up results of up to 24 months from 29 treated patients across the U.S. and Europe.
In the 7MM population, there will be 81,000 cases of Huntington's disease overall in 2022. In the 7MM, the US had the highest number of frequently occurring cases of Huntington's disease, followed by Germany
In Germany, there were correspondingly 300, 700, 1,200, and 2,000 cases of Huntington's disease among people aged 20 to 39, 40 to 49, 50 to 59, and 60 or older in 2022.
In the 7MM, there were 39,000 treated instances of Huntington's disease overall in 2022; however, this number could rise during the projection period (2023–2022)
Key Huntington's Disease Companies: Teva Pharmaceutical, Annexon Biosciences, Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others
Key Huntington's Disease Therapies: AUSTEDO (deutetrabenazine/SD-809), ANX005, Pridopidine(ACR-16; Huntexil), Ingrezza (valbenazine), SOM3355(bevantolol), ANX005, VX15/2503 (pepinemab), SAGE-718, AMT-130/ intrastriatal rAAV5-miHTT, RO7234292, Tominersen, Valbenazine, Pepinemab, SRX246, WVE-003, LPM3770164, SOL-175, and others
The Huntington's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Huntington's Disease pipeline products will significantly revolutionize the Huntington's Disease market dynamics.
Huntington's Disease Overview
Huntington's disease (HD) is a progressive and inherited neurological disorder that affects the brain's nerve cells, leading to gradual deterioration of cognitive, motor, and psychiatric functions. HD is caused by a mutation in the HTT gene, which produces a protein called huntingtin. The mutation leads to the production of an abnormal form of the huntingtin protein, which accumulates in neurons and disrupts their function.
Get a Free sample for the Huntington's Disease Market Report:
Huntington's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Huntington's Disease Epidemiology Segmentation:
The Huntington's Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Huntington's Disease
Prevalent Cases of Huntington's Disease by severity
Gender-specific Prevalence of Huntington's Disease
Diagnosed Cases of Episodic and Chronic Huntington's Disease
Download the report to understand which factors are driving Huntington's Disease epidemiology trends @ Huntington's Disease Epidemiology Forecast
Huntington's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Huntington's Disease market or expected to get launched during the study period. The analysis covers Huntington's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Huntington's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Huntington's Disease Therapies and Key Companies
AUSTEDO (deutetrabenazine/SD-809): Teva Pharmaceutical
ANX005: Annexon Biosciences
Pridopidine(ACR-16; Huntexil): Prilenia Therapeutics
Ingrezza (valbenazine): Neurocrine Biosciences
SOM3355(bevantolol): Som Biotech
ANX005: Annexon Biosciences
VX15/2503 (pepinemab): Vaccinex
SAGE-718: Sage Therapeutics
AMT-130/ intrastriatal rAAV5-miHTT: UniQure Biopharma
RO7234292: Roche
Tominersen: Ionis Pharmaceuticals
Valbenazine: Neurocrine Biosciences
Pepinemab: Vaccinex
SRX246: Azevan Pharmaceuticals
WVE-003: WaVe life Sciences
LPM3770164: Luye Pharma Group
SOL-175: SOLA Biosciences
Discover more about therapies set to grab major Huntington's Disease market share @ Huntington's Disease Treatment Market
Huntington's Disease Market Strengths
As adult-onset Huntington's disease is more common than juvenile Huntington's disease, so with growing geriatricpopulation more elderly patients will be diagnosed with HD knowledge
Huntington's Disease Market Opportunities
Huntington's disease is a rare condition thus, companies developing treatment options for the same can possess several advantages like premium pricing, an Orphan Designation, which comes along with 7 years of market exclusivity in the US, clinical trial subsidies, reduced regulatory fees, and several other benefits.
Scope of the Huntington's Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Huntington's Disease Companies: Teva Pharmaceutical, Annexon Biosciences, Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others
Key Huntington's Disease Therapies: AUSTEDO (deutetrabenazine/SD-809), ANX005, Pridopidine(ACR-16; Huntexil), Ingrezza (valbenazine), SOM3355(bevantolol), ANX005, VX15/2503 (pepinemab), SAGE-718, AMT-130/ intrastriatal rAAV5-miHTT, RO7234292, Tominersen, Valbenazine, Pepinemab, SRX246, WVE-003, LPM3770164, SOL-175, and others
Huntington's Disease Therapeutic Assessment: Huntington's Disease current marketed and Huntington's Disease emerging therapies
Huntington's Disease Market Dynamics: Huntington's Disease market drivers and Huntington's Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Huntington's Disease Unmet Needs, KOL's views, Analyst's views, Huntington's Disease Market Access and Reimbursement
To know more about Huntington's Disease companies working in the treatment market, visit @ Huntington's Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Huntington's Disease Market Report Introduction
2. Executive Summary for Huntington's Disease
3. SWOT analysis of Huntington's Disease
4. Huntington's Disease Patient Share (%) Overview at a Glance
5. Huntington's Disease Market Overview at a Glance
6. Huntington's Disease Disease Background and Overview
7. Huntington's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Huntington's Disease
9. Huntington's Disease Current Treatment and Medical Practices
10. Huntington's Disease Unmet Needs
11. Huntington's Disease Emerging Therapies
12. Huntington's Disease Market Outlook
13. Country-Wise Huntington's Disease Market Analysis (2020–2034)
14. Huntington's Disease Market Access and Reimbursement of Therapies
15. Huntington's Disease Market Drivers
16. Huntington's Disease Market Barriers
17. Huntington's Disease Appendix
18. Huntington's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Casper Network Advances Regulated Tokenization With ERC-3643 Standard
- Forex Expo Dubai Wins Guinness World Recordstm With 20,021 Visitors
- Superiorstar Prosperity Group Russell Hawthorne Highlights New Machine Learning Risk Framework
- Freedom Holding Corp. (FRHC) Shares Included In The Motley Fool's TMF Moneyball Portfolio
- Versus Trade Launches Master IB Program: Multi-Tier Commission Structure
- Ozzy Tyres Grows Their Monsta Terrain Gripper Tyres Performing In Australian Summers
Comments
No comment